Concepedia

Mark Allison

MA

Statistics

Publications

10

Citations

646

H-Index

10

Active since

2005

Affiliations

Celerion (United States)(Current)

Novartis (Switzerland)

Daiichi Sankyo (United States)

Daiichi Sankyo (Germany)

Comprehensive Clinical Research

Mark Allison is an author at Celerion (United States) specializing in pharmacology, clinical pharmacology, and pharmacokinetics.

Publications per year

2005–2018

10

Publications

10

Multiple doses of sclerostin antibody romosozumab in healthy men and postmenopausal women with low bone mass: A randomized, double-blind, placebo-controlled study

Desmond Padhi, Mark Allison, Alan Kivitz et al. · The Journal of Clinical Pharmacology · 2013 · 184 citations · Full text

, , +15

A phase 1 study of ACE‐536, a regulator of erythroid differentiation, in healthy volunteers

Kenneth M. Attie, Mark Allison, Ty McClure et al. · American Journal of Hematology · 2014 · 108 citations · Full text

, , +13

Concomitant Tacrolimus and Micafungin Pharmacokinetics in Healthy Volunteers

Mary F. Hébert, David K. Blough, Robert Townsend et al. · The Journal of Clinical Pharmacology · 2005 · 93 citations · Full text

, , +13

Steady-State Pharmacokinetic and Safety Profiles of Voriconazole and Ritonavir in Healthy Male Subjects

Ping Liu, Grover Foster, Kuan Gandelman et al. · Antimicrobial Agents and Chemotherapy · 2007 · 78 citations · Full text

, , +15

Pharmacokinetic interaction between verapamil and everolimus in healthy subjects

John M. Kovarik, D. Beyer, M. N. Bizot et al. · British Journal of Clinical Pharmacology · 2005 · 54 citations · Full text

, , +14

1–5 of 10